Health & Bio
Arvinas Veppanu wins FDA nod as first PROTAC to market
May 1 approval for protein degrader vepdegestrant targets ESR1-mutant ER+/HER2− advanced breast cancer. Novel modality milestone.
Primary sources · 2
May 1 approval for protein degrader vepdegestrant targets ESR1-mutant ER+/HER2− advanced breast cancer. Novel modality milestone.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.